Who Paid My Doc
Jonathan Kochav
Adult Congenital Heart Disease New York, NY Medical Doctor
NPI 1700298023 CMS profile 952898
161 Fort Washington Ave, New York, NY 10032
General payments
$1,368
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jonathan Kochav of New York, NY is reported in the CMS Open Payments database as having received $1,368 across 26 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $24 | 1 | |
| 2023 | General | $103 | 3 | |
| 2022 | General | $356 | 6 | |
| 2021 | General | $321 | 7 | |
| 2020 | General | $266 | 6 | |
| 2019 | General | $298 | 3 |
Beside peers
- Jonathan Kochav
- Adult Congenital Heart Disease median
- Middle half of Adult Congenital Heart Disease
- National median
In program year 2025, general payments to Jonathan Kochav were reported at $24. Among 56 Adult Congenital Heart Disease profiles paid that year, the median was $272 and the middle half received between $51 and $642.
Show as a table
| Year | Jonathan Kochav | Adult Congenital Heart Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $298 | $202 | $71–$498 | $163 |
| 2020 | $266 | $127 | $28–$236 | $114 |
| 2021 | $321 | $138 | $34–$310 | $132 |
| 2022 | $356 | $275 | $125–$1,572 | $149 |
| 2023 | $103 | $215 | $58–$1,454 | $160 |
| 2024 | $0 | $273 | $84–$801 | $164 |
| 2025 | $24 | $272 | $51–$642 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$25,575
Medicare patients
76
Services billed
302
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Heart failure | 51% | |
| Atrial fibrillation | 45% | |
| Ischemic heart disease | 39% | |
| Arthritis | 32% | |
| Chronic kidney disease | 26% | |
| Diabetes | 25% | |
| Depression | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
26 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Congenital Heart Disease in New York
Robert Sommer
Adult Congenital Heart Disease · New York, NY
Georges Ephrem
Adult Congenital Heart Disease · Valhalla, NY
Harsimran Singh
Adult Congenital Heart Disease · New York, NY
Noa Zemer Wassercug
Adult Congenital Heart Disease · New York, NY
Yamini Krishnamurthy
Adult Congenital Heart Disease · New York, NY
Su Yuan
Adult Congenital Heart Disease · New York, NY
Related records
Adult Congenital Heart Disease in New York
Practitioners in the same specialty and state, ranked by reported value.
All Adult Congenital Heart Disease
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.